Amedisys Inc (NASDAQ:AMED) has received a consensus recommendation of “Hold” from the eleven research firms that are presently covering the company, Marketbeat reports. Eight equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $32.86.
Several research analysts have recently weighed in on AMED shares. Zacks Investment Research cut shares of Amedisys from a “buy” rating to a “hold” rating in a report on Tuesday, September 29th. Oppenheimer reaffirmed a “market perform” rating on shares of Amedisys in a report on Tuesday, October 6th. Piper Jaffray reaffirmed a “neutral” rating and issued a $45.00 price target (up previously from $42.00) on shares of Amedisys in a report on Friday, November 6th. Mizuho cut shares of Amedisys from a “buy” rating to a “neutral” rating and set a $45.00 price target on the stock. in a report on Wednesday, November 11th. Finally, Jefferies Group decreased their price target on shares of Amedisys from $15.00 to $12.00 and set a “hold” rating on the stock in a report on Thursday, November 26th.
In related news, major shareholder North Tide Capital, Llc sold 191,400 shares of the firm’s stock in a transaction that occurred on Wednesday, October 28th. The shares were sold at an average price of $39.86, for a total transaction of $7,629,204.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
A hedge fund recently bought a new stake in Amedisys stock. Northcoast Asset Management purchased a new position in Amedisys Inc (NASDAQ:AMED) during the third quarter, according to its most recent filing with the SEC. The hedge fund purchased 6,614 shares of the company’s stock, valued at approximately $251,000.
Shares of Amedisys (NASDAQ:AMED) opened at 40.46 on Thursday. The company has a 50 day moving average of $40.61 and a 200 day moving average of $41.02. The company’s market cap is $1.36 billion. Amedisys has a 52 week low of $24.81 and a 52 week high of $48.34.
Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.34 earnings per share for the quarter, hitting the consensus estimate of $0.34. The firm earned $326.50 million during the quarter, compared to the consensus estimate of $312.22 million. During the same period in the previous year, the company posted $0.28 EPS. The company’s revenue for the quarter was up 8.7% compared to the same quarter last year. On average, analysts expect that Amedisys will post $1.43 EPS for the current year.
Amedisys, Inc. (NASDAQ:AMED) is a health care at home company. Amedisys delivers home health and hospice care to more than 360,000 patients each year. The Company has care network across 34 states. As of December 31, 2014, it owned and operated 316 Medicare-certified home health care centers and 80 Medicare-certified hospice care centers. The Company operates through two segments: home health and hospice. The Company’s home health segment delivers a range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with the essential activities of daily living. The Company’s hospice segment provides palliative care and comfort to terminally ill patients and their families.